We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.50 | 0.98% | 1,599.00 | 1,599.50 | 1,600.50 | 1,600.00 | 1,575.00 | 1,579.50 | 5,149,016 | 16:35:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.37 | 65.87B |
Date | Subject | Author | Discuss |
---|---|---|---|
12/7/2015 21:55 | Scottishfield, Thanks for your contribution! I sometimes forget what I was about to say!!! | jadeticl3 | |
11/7/2015 12:51 | Companies should only pay a dividend if they have not got a better use for the money. The new budget rules on dividend taxes will align the UK with the US. There companies tend to pay dividends sparingly because of double taxation. It is a major reason why buy backs are used more often in the US than the UK. | greenpastures2 | |
09/7/2015 16:14 | Earnings yield is more important than distribution yield in any case. | hpcg | |
08/7/2015 17:00 | I think its a good thing sometimes. Aviva used to have a high yield and everytime the results came around the focus was solely on the dividend - this lead to a lot of speculation and column inches and I think it took the focus off the results. They cut it to a more sustainable level and the share price has performed strongly. I'm not saying that it would be the same with GSK, but if its becomes close to unsustainable cut it. | dr biotech | |
08/7/2015 16:54 | Appreciate that perspective and many are in a similar position, GSK will want to buy out the remaining Novartis OTC stake imv and that will require a big investment. I can see the longer term potential here, not currently holding. | essentialinvestor | |
08/7/2015 16:26 | I'd certainly view it as negative if they "rebase", a sleazy euphemism for cut, because I only invest in shares for income. In line with my strat, I wouldn't sell unless such a cut drops the yield to the FTSE but I certainly would not be pleased about it because it would hit my income. Cuts are the risk I take for investing in shares for income but I see nothing positive about them at all. I don't believe in trading lower divis for growth for two reasons. First, I don't care about share prices and second even if I did, I have no faith that cutting the divi would produce a measurable trade off in share price growth. The difference between GSK and those others you mention is that I don't think that TSCO etc made a similar commitment to a certain divi figure for a three year period as GSK has done. So I'd guess it is much more likely than not that GSK will stick to their plan. In any event there's little point in speculating about it for me, because it doesn't influence my reasons for holding or selling the share. | anhar | |
08/7/2015 12:57 | Rebasing of the dividend in 2016 IMV, as per TSCO, CNA, SBRY... it's a long list. Just to add I would not view it as a negative development if in the context of an enhanced growth orientated strategy, this is speculation on my part. | essentialinvestor | |
08/7/2015 12:07 | I've got no interest in brokers' views. No divis are guaranteed but I'm inclined to believe the GSK 80p three year commitment plus the 20p special for the first year. That makes a yield of about 5.9% at 1,347p even without the special, which is a big premium over the FTSE. Whatever happens though I'll stick to my income strat and hold GSK until its yield falls to the FTSE or forever, whichever comes first. Even my own beliefs about the GSK commitment are irrelevant to the strat. | anhar | |
08/7/2015 10:21 | The Liberum take on GSK is interesting. The central theme is that the status quo cannot be maintained, the dividend commitment over 3 years may lack credibility given the number of times GSK has not delivered on targets. They appear to see a dividend cut as part of a new strategic plan giving GSK more flexibility to acquire, for example, the remainder of Novartis's stake in the OTC business and further invest in their franchises to drive growth. | essentialinvestor | |
08/7/2015 08:01 | Let's face it, the European experiment has failed - political, economic and social | tradermichael | |
06/7/2015 06:47 | I think you are wrong Monty. If Greece leaves the Euro the Germans and, to a lesser extent, the French will pay for the exit. The Euro requires a quasi national constitution in order to work not the petty national squabbling that is the current make up of the EU. The ECB has to take control, not the politicians. That means printing money and handing that money to the Greeks, Irish, Portugese, Spanish and Italians. In other words regional development in an international situation. | darias | |
06/7/2015 06:09 | The non tax payer Greeks are in for a shock. How stupid are they. | montyhedge | |
05/7/2015 20:48 | Seems Greeks are going to get away with it. | racg | |
05/7/2015 20:25 | What price tomorrow? | tompion | |
03/7/2015 21:34 | Huge multi year support in this area. free stock charts from uk.advfn.com | tim 3 | |
03/7/2015 21:24 | Agreed. Give us the methadone breezers, Witty! | racg | |
03/7/2015 20:54 | Essential, GSK should supply PI shareholders with their products for free, especially those tablets which treat nervous disorders as the problem has probably been caused by the company! | jadeticl3 | |
02/7/2015 16:22 | There is great long term(3-5 years) value here imv, very tradable in the meantime. Would not like to count how many of their products I use, at least two, including one off label - for which I needed to sign a multi page disclaimer ) | essentialinvestor | |
02/7/2015 16:18 | Sitting on a few | badtime | |
02/7/2015 15:41 | added a few | phillis | |
01/7/2015 11:28 | Sold a few but keep the majority. | essentialinvestor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions